Alterity Therapeutics (ASX:ATH), (NASDAQ:ATHE) is a biotechnology company dedicated to developing and commercializing therapies to treat and improve the lives of patients suffering from neurodegenerative diseases, particularly Parkinson's disease and other movement disorders. Alterity's research focuses on creating novel drug candidates that can modify disease processes, aiming to halt or reverse the progression of these debilitating conditions. The company is pioneering efforts in identifying and targeting cellular mechanisms that are thought to be critical in the development and progression of neurological diseases. One of their flagship projects involves the development of ATH434, a small molecule drug designed to reduce the accumulation of pathological proteins implicated in neurodegeneration. Alterity Therapeutics' objectives include advancing its portfolio of drug candidates through clinical trials, securing partnerships for development and commercialization, and ultimately bringing new therapeutic options to patients and healthcare providers to address the unmet needs in neurodegenerative care.